Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
Recruiting
N/A
Interventional Study
Breast Cancer
Lymph Node Metastasis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 100 (estimated)
- Sponsor
- UNC Lineberger Comprehensive Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes. Researchers aim to understand if ctDNA detection can identify patients at higher risk of recurrence and guide better treatment decisions. A key aspect is the inclusion of…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
Inclusion Criteria:
1. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
2. Subjects are willing and able to co…
Contacts